SG48460A1 - External therapeutic composition for dermatitis - Google Patents
External therapeutic composition for dermatitisInfo
- Publication number
- SG48460A1 SG48460A1 SG1996010182A SG1996010182A SG48460A1 SG 48460 A1 SG48460 A1 SG 48460A1 SG 1996010182 A SG1996010182 A SG 1996010182A SG 1996010182 A SG1996010182 A SG 1996010182A SG 48460 A1 SG48460 A1 SG 48460A1
- Authority
- SG
- Singapore
- Prior art keywords
- dermatitis
- therapeutic composition
- external therapeutic
- clathrate
- aqueous solution
- Prior art date
Links
- 201000004624 Dermatitis Diseases 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 4
- 239000007864 aqueous solution Substances 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 239000003470 adrenal cortex hormone Substances 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Carriers, Traveling Bodies, And Overhead Traveling Cranes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7346006A JP2920611B2 (ja) | 1995-12-11 | 1995-12-11 | 皮膚炎の治療外用剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG48460A1 true SG48460A1 (en) | 1998-04-17 |
Family
ID=18380498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG1996010182A SG48460A1 (en) | 1995-12-11 | 1996-06-29 | External therapeutic composition for dermatitis |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5885978A (da) |
| EP (1) | EP0780129B1 (da) |
| JP (1) | JP2920611B2 (da) |
| KR (1) | KR0181763B1 (da) |
| CN (1) | CN1153571C (da) |
| AT (1) | ATE290883T1 (da) |
| AU (1) | AU705996B2 (da) |
| CA (1) | CA2173403C (da) |
| DE (1) | DE69634472T2 (da) |
| DK (1) | DK0780129T3 (da) |
| ES (1) | ES2240987T3 (da) |
| SG (1) | SG48460A1 (da) |
| TW (1) | TW431889B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826656D0 (en) | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| IT1319665B1 (it) * | 2000-11-17 | 2003-10-23 | Pharma Biotech Ltd | Addotti di corticosteroidi con polimeri polisaccaridici naturali. |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| EP1216712A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
| US7897161B2 (en) * | 2002-06-03 | 2011-03-01 | Cac Corporation | External medicine for treating dermatitis |
| FR2842106B1 (fr) * | 2002-07-11 | 2006-07-14 | Centre Nat Rech Scient | Dispersions aqueuses de particules nanometriques ou micrometriques pour l'encapsulation de composes chimiques |
| KR100564153B1 (ko) * | 2002-11-28 | 2006-03-27 | 주식회사 에이치 엔 비티 | 아토피성 피부염을 개선시키는 조성물 |
| EP1761283A2 (en) * | 2004-06-07 | 2007-03-14 | California Institute Of Technology | Biodegradable drug-polymer delivery system |
| WO2005121329A2 (en) * | 2004-06-11 | 2005-12-22 | Syngenta Limited | Method for ameliorating an inflammatory skin condition |
| JP5456802B2 (ja) * | 2012-01-23 | 2014-04-02 | 株式会社Cac | 細胞遊走促進剤及び創傷治療用の経皮吸収剤 |
| JP6313118B2 (ja) * | 2014-05-16 | 2018-04-18 | 株式会社Cac | IgE抑制剤 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5231019B2 (da) * | 1973-10-16 | 1977-08-12 | ||
| US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| JPS61246130A (ja) * | 1985-04-24 | 1986-11-01 | Japan Fine Chem Kk | 水性皮膚及び毛髪化粧料 |
| US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| ES2037385T3 (es) * | 1988-01-14 | 1993-06-16 | Akzo N.V. | Un procedimiento de manufactura de una preparacion farmaceutica para administracion local. |
| US5019562A (en) * | 1988-01-19 | 1991-05-28 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Growth inhibiting agent and the use thereof |
| JPH0795311B2 (ja) * | 1988-06-30 | 1995-10-11 | 日本電気株式会社 | 二重化処理装置 |
| US5229370A (en) * | 1988-08-15 | 1993-07-20 | Ammeraal Robert N | Water soluble branched beta cyclodextrin steroid complex |
| JP2681527B2 (ja) * | 1990-02-15 | 1997-11-26 | ジャパンファインケミカル株式会社 | 細胞活性促進外用剤 |
| GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
| JP2578048B2 (ja) * | 1992-05-22 | 1997-02-05 | 株式会社 シーエーシー | 循環瀘過装置 |
| US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| JP3535883B2 (ja) * | 1993-06-25 | 2004-06-07 | 井関農機株式会社 | 作業機連結装置 |
| JPH0756417A (ja) * | 1993-08-09 | 1995-03-03 | Ricoh Co Ltd | 回転型現像装置 |
| JP2772619B2 (ja) * | 1994-06-28 | 1998-07-02 | 株式会社シーエーシー | 多糖類水溶液用循環風呂 |
-
1995
- 1995-12-11 JP JP7346006A patent/JP2920611B2/ja not_active Expired - Lifetime
-
1996
- 1996-03-20 TW TW085103373A patent/TW431889B/zh not_active IP Right Cessation
- 1996-04-03 CA CA002173403A patent/CA2173403C/en not_active Expired - Lifetime
- 1996-04-03 US US08/626,963 patent/US5885978A/en not_active Expired - Lifetime
- 1996-04-04 AU AU50560/96A patent/AU705996B2/en not_active Expired
- 1996-04-10 EP EP96302509A patent/EP0780129B1/en not_active Expired - Lifetime
- 1996-04-10 DK DK96302509T patent/DK0780129T3/da active
- 1996-04-10 AT AT96302509T patent/ATE290883T1/de active
- 1996-04-10 ES ES96302509T patent/ES2240987T3/es not_active Expired - Lifetime
- 1996-04-10 DE DE69634472T patent/DE69634472T2/de not_active Expired - Lifetime
- 1996-06-03 CN CNB961053372A patent/CN1153571C/zh not_active Expired - Lifetime
- 1996-06-07 KR KR1019960020250A patent/KR0181763B1/ko not_active Expired - Lifetime
- 1996-06-29 SG SG1996010182A patent/SG48460A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0780129A3 (en) | 2000-07-19 |
| KR970032871A (ko) | 1997-07-22 |
| DE69634472D1 (de) | 2005-04-21 |
| US5885978A (en) | 1999-03-23 |
| AU705996B2 (en) | 1999-06-03 |
| DK0780129T3 (da) | 2005-06-20 |
| CA2173403A1 (en) | 1997-06-12 |
| CN1151866A (zh) | 1997-06-18 |
| TW431889B (en) | 2001-05-01 |
| KR0181763B1 (ko) | 1999-05-01 |
| ES2240987T3 (es) | 2005-10-16 |
| CA2173403C (en) | 2000-05-16 |
| JPH09157171A (ja) | 1997-06-17 |
| EP0780129B1 (en) | 2005-03-16 |
| ATE290883T1 (de) | 2005-04-15 |
| AU5056096A (en) | 1997-06-19 |
| JP2920611B2 (ja) | 1999-07-19 |
| DE69634472T2 (de) | 2006-02-16 |
| CN1153571C (zh) | 2004-06-16 |
| EP0780129A2 (en) | 1997-06-25 |
| HK1004979A1 (en) | 1998-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG48460A1 (en) | External therapeutic composition for dermatitis | |
| HU9200048D0 (en) | Process for treating androgene deseases | |
| IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
| HUT74452A (en) | Preparation for substitution therapy, containing at least one progestogen and at least one extrogen | |
| DE69736745D1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
| PL301841A1 (en) | Pharmaceutical agent and method of obtaining same | |
| IL121126A0 (en) | Method of increasing expression of molecular chaperon by an eukarytic cell | |
| IT1255390B (it) | Prodotti farmaceutici per curare malattie tumorali e procedimento per la loro preparazione | |
| ID28160A (id) | Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat. | |
| DE69731540D1 (de) | Behandlung von diarrhoe | |
| PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
| GB9717617D0 (en) | Process for glucan preparation and therapeutic uses of glucan | |
| MY138240A (en) | Method of treating androgenic alopecia with 5- alpha reductase inhibitors. | |
| DE69320646D1 (de) | Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff | |
| CA2173457A1 (en) | Use of 5-alpha reductase inhibitorsand compositions for treating androg enic alopecia | |
| NO994275D0 (no) | Nikotinsyrepreparater til behandling av hyperlipidemi og tilknyttede fremgangsmÕter | |
| NO981282L (no) | Calcitriolderivater og deres anvendelser | |
| FR08C0001I1 (da) | ||
| DE69328635D1 (de) | Verwendung eines stoffgemisches enthaltend alpha hydroxy organische säure zur herstellung eines arzneimittels zur behandlung von kleinen mundgeschwüren | |
| HUT68239A (en) | Process for producing inclusion complexes of nimesulide alkali salts with cyclodextrins or cyclodextrin derivatives and pharmaceutical preparations containing them | |
| AU573262B2 (en) | Covalently bound heparin-antithrombin iii complex | |
| AP9801416A0 (en) | Method Of treating a plant disease. | |
| ES2165382T3 (es) | Agentes antiateroescleroticos. | |
| UA49572A (uk) | Спосіб лікування затяжних пневмоній | |
| UA28777A (uk) | Спосіб лікування алкогольного делірію, ускладненого набряком-набуханням головного мозку |